Table 1.
Population characteristics.
| Group without GHRT | Group with GHRT | p-Value | |
|---|---|---|---|
| Total population | n (%) | n (%) | |
| 107 | 17 | ||
| Gender | 0.38 | ||
| Female | 60 (56.1%) | 7 (41.2%) | |
| Male | 47 (43.9%) | 10 (58.8%) | |
| NF1 | 39 (36.5%) | 3 (17.7%) | 0.21 |
| Tumor type | |||
| Pilocytic astrocytoma (grade I) | 95 (88.8%) | 12 (70.6%) | 0.02 |
| Astrocytoma (grade II) | 2 (1.9%) | 3 (17.6%) | |
| Oligoastrocytoma (grade II) | 3 (2.8%) | 0 (0%) | |
| Oligodendroglioma (grade II) | 3 (2.8%) | 0 (0%) | |
| Ganglioglioma (grade II) | 4 (3.7%) | 2 (11.8%) | |
| Biopsy (followed by chemo or RT or simple monitoring) | 22 (20.6%) | 6 (35.3%) | 0.21 |
| First-line treatments (can be combined) | |||
| Subtotal resection | 26 (24.3%) | 6 (35.3%) | 0.37 |
| Complete resection | 9 (8.4%) | 0 (0%) | 1 |
| Chemotherapy | 53 (49.5%) | 15 (88.2%) | 0.003 |
| Radiotherapy | 7 (6.5%) | 1 (5.9%) | 0.99 |
| First-line treatments in detail | |||
| Surgery only | 19 (17.8%) | 1 (5.9%) | 0.3 |
| Surgery + RT | 3 (2.8%) | 0 (0%) | 1 |
| Surgery + chemo | 14 (13.1%) | 5 (29.4%) | 0.14 |
| Surgery + RT + chemo | 1 (0.9%) | 0 (0%) | 1 |
| Chemo only | 37 (34.6%) | 9 (52.9%) | 0.18 |
| RT only | 2 (1.9%) | 0 (0%) | 1 |
| Chemo + RT | 1 (0.9%) | 1 (5.9%) | 0.26 |
| Simple monitoring | 30 (28%) | 1 (5.9%) | 0.07 |
NF1: Neurofibromatosis type 1; GHRT: growth hormone replacement therapy; RT: radiotherapy; Chemo: chemotherapy.